30 January 2024
30 January 2024
Despite GDPR, EU countries can make their own data protection laws. In the US, data protection laws differ between states. This can make it difficult for a sponsor to scale.
The US Food and Drug Administration (FDA) halted the Phase II trial in June 2022 after some patients were reported to be suffering from severe hypomagnesemia.
Results from a Phase III trial indicated that adding MSD’s blockbuster drug boosted survival rates in advanced bladder cancer patients.
An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.
Asieris presented the positive results at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.
The company plans to begin the Phase II trial for prostate cancer treatment in March.
Deltacel demonstrated early efficacy with good safety and tolerability outcomes in the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
